Exelixis, Merck enter clinical development collaboration to evaluate zanzalintinib in combo with Keytruda in HNSCC and ...
Exelixis, Inc. and Merck, known as MSD outside of the United States and Canada, announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) …